Floatz logo

Zenocutuzumab

Head and Neck Cancer

monoclonal_antibodyDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

142 Active assets in the Head and Neck Cancer cohort.

Asset / SponsorPhaseRating
NEPENTHE
Instituto Nacional de Cancer, Brazil
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 3BB
LIDOCAINE
Instituto Nacional de Cancer, Brazil
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
FILGRASTIM
University of Colorado, Denver
Phase 2BB

View all 50 →

Same molecule, other indications

Zenocutuzumab is also rated in:

Solid Tumours Harboring NRG1 FusionDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →